US Patent

US12329742 — Pharmaceutical composition of darolutamide

Formulation · Assigned to Orion Oyj · Expires 2042-06-17 · 16y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical composition of darolutamide, specifically a tablet formulation for oral administration.

USPTO Abstract

The present invention relates to a pharmaceutical composition for oral administration, particularly in the form of a tablet, comprising darolutamide or a pharmaceutically acceptable salt thereof as an active ingredient. Darolutamide is a potent androgen receptor (AR) modulator useful in the treatment of cancer, particularly AR dependent cancer such as prostate cancer, and other diseases where AR antagonism is desired.

Drugs covered by this patent

Patent Metadata

Patent number
US12329742
Jurisdiction
US
Classification
Formulation
Expires
2042-06-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.